Boerhaave’s syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report Authors: Jason M Aubrey, Chance Benner, Geoffrey T Lam Published: 2026 ABSTRACT AbstractBackgroundGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes and weight loss, with well known gastrointestinal side effects including nausea, vomiting, and delayed gastric emptying. While mucosal injuries such as Mallory Weiss tears have been reported, full thickness esophageal perforation has not previously been described. We report the first documented case of Boerhaave’s syndrome associated with GLP-1 RA use, highlighting the potential for rare but life threatening complications following abrupt reinitiation at high doses.Case presentationA previously healthy woman in her 50s presented with vasopressor dependent shock and respiratory failure requiring intubation following severe nausea, emesis, and acute chest pain. She had restarted semaglutide at the maximum 2.4 mg weekly dose the day prior to symptom onset, after several months off therapy and without dose titration. Imaging revealed pneumomediastinum and bilateral pleural effusions. Esophagram confirmed a contained esophageal perforation. She was managed with endoscopic stent placement, nasojejunal feeding, and chest tube drainage, followed by clinical improvement and discharge. Two months later, she was readmitted with necrotizing pneumonia. Imaging and endoscopy revealed an esophagopleural fistula, abscess, and migrated stent. She underwent left thoracotomy, abscess drainage, decortication, and wedge resection of necrotic lung. The perforation site was reinforced with an intercostal muscle flap, and a PEG tube was placed. Postoperatively, at 10-month follow up she was on a regular diet, PEG tube removed, and esophagus was healed on EGD. She was advised to permanently discontinue GLP-1 RAs.ConclusionsThis case underscores a previously unreported but serious complication of GLP-1 RA therapy, transmural esophageal rupture, likely precipitated by drug induced gastroparesis and forceful emesis. Restarting semaglutide at a high dose without titration after a prolonged interruption likely increased vulnerability to injury. Clinicians should maintain a high index of suspicion for esophageal complications in patients presenting with chest pain and vomiting during GLP-1 RA initiation or reinitiation. Early multidisciplinary management is crucial to optimizing outcomes in this rare but life-threatening scenario.Keywords: Esophageal perforation, Boerhaave syndrome, Esophageal diseases, Glucagon-like peptide-1 receptor agonists, Glucagon-like peptide-1, Weight loss agent, Drug-induced gastroparesis, Semaglutide Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have become a mainstay in the management of type 2 diabetes mellitus and obesity due to their ability to enhance glucose dependent insulin secretion, suppress appetite, and delay gastric emptying. Although these agents are generally well tolerated, gastrointestinal adverse effects such as nausea, vomiting, and abdominal discomfort are frequently reported. In some cases, impaired gastric motility has been implicated in more serious sequelae, including symptomatic gastroparesis, bezoar formation, and aspiration events. These risks appear to be magnified during periods of dose escalation or when therapy is restarted abruptly at high doses without titration. Boerhaave’s syndrome, or spontaneous transmural esophageal rupture, is a rare but life threatening condition typically triggered by forceful emesis. While prior reports and FDA safety labeling have noted associations between GLP-1 RA use and Mallory Weiss tears, full thickness esophageal perforation has not previously been described. Here, we present the first reported case of Boerhaave’s syndrome following reinitiation of semaglutide at the maximum dose after a prolonged treatment gap. This case highlights a novel and severe gastrointestinal complication of GLP-1 RA therapy and raises concern for an underrecognized risk in patients with poor medication tolerance or rapid reinitiation. We discuss possible mechanistic links between drug induced delayed gastric emptying, central emetic pathway activation, and esophageal injury, while emphasizing the need for careful titration and multidisciplinary intervention. Case presentation A previously healthy woman in her 50s presented in shock requiring vasopressor support and respiratory failure necessitating mechanical ventilation following an episode of nausea, vomiting, and acute-onset chest pain. Vitals on presentation were heart rate 120’s, blood pressure 80/40’s, and respiratory rate 28 saturating 90–94% on 5LNC. The patient reported initiating semaglutide therapy (0.25 mg weekly) one year prior for weight loss. She gradually titrated to a dose of 2.4 mg weekly. She lost approximately 30 lbs. After a lapse in insurance coverage, she discontinued the medication for several months. She resumed semaglutide at the weekly maximum dose of 2.4 mg the day prior to presentation, without undergoing a dose titration period. CT imaging revealed pneumomediastinum and small bilateral pleural effusions. An esophagram demonstrated a contained esophageal perforation. The patient was initiated on broad-spectrum antibiotics and antifungal therapy, and gastroenterology was consulted for endoscopic management. Thoracic surgery was consulted and recommended endoscopic interrogation and stenting due to the contained nature of the perforation. Esophagogastroduodenoscopy (EGD) identified a 20-mm esophageal perforation located 38 cm from the incisors. (Fig. 1) A 23-mm × 12-cm fully covered Boston Scientific esophageal stent was placed endoscopically and secured with endoscopic suturing, and a nasojejunal feeding tube was inserted for enteral nutrition. Follow-up esophagram confirmed appropriate stent positioning without contrast extravasation. A left-sided chest tube was placed for management of the pleural effusion. The patient demonstrated significant clinical improvement, was weaned off vasopressors and extubated on hospital day 4, and subsequently transferred from the intensive care unit on hospital day 5. A month after the original stent placement, a scheduled repeat EGD was performed, which demonstrated a persistent esophageal perforation. Given the size of the perforation and the friable nature of the surrounding tissue, the multidisciplinary team elected to maintain endoscopic stent coverage to facilitate sealing of the defect. A 20 mm by 12 cm fully covered self expanding metal stent was placed and secured with endostitches. A post procedure esophagram demonstrated good coverage of the perforation without evidence of extraluminal contrast. Plan was to follow-up in 4-weeks for repeat EGD. Esophagogastroduodenoscopy demonstrates a 20 mm perforation at the gastroesophageal junction. A Boston Scientific 23 mm x 12 cm fully covered stent was placed Two months following her initial hospitalization, the patient was readmitted with necrotizing pneumonia of the left lower lobe. Imaging demonstrated migration of the esophageal stent, which was subsequently retrieved endoscopically. During endoscopy, a suspected blind-ended tract at the distal esophagus was identified without evidence of purulent drainage. CT imaging performed post-procedure suggested an esophagopleural fistula and abscess formation. (Fig. 2) Follow-up esophagram revealed free contrast extravasation into the left pleural cavity. EGD was repeated with replacement of a fully covered stent. Thoracic surgery was consulted, and decision was made to pursue left thoracotomy, abscess drainage, decortication, repair of esophageal perforation, and percutaneous endoscopic gastrostomy (PEG) tube placement. Intraoperatively, murky, purulent fluid was encountered upon entry into the thoracic cavity. The left lower lobe was densely adherent to the abscess cavity and contained necrotic areas requiring a wedge resection. A large extrapleural empyema was evacuated, and fibrinous and inflammatory rind was extensively debrided. The esophageal perforation site was noted to be friable and unsuitable for primary closure; therefore, an intercostal muscle flap was mobilized to place over the site of perforation. The thoracic cavity was irrigated until the effluent was clear, and two chest tubes were placed for drainage. Postoperatively, the patient was successfully weaned from vasopressor support and maintained on PEG tube feeds while kept nil per os. A repeat esophagram on postoperative day 14 demonstrated no evidence of leak. Her diet was gradually advanced, and by 3 months, she was tolerating adequate oral intake, allowing for PEG tube removal. The esophageal stent was removed 1 month postoperatively. (Fig. 3) She was advised to permanently discontinue semaglutide and other GLP-1 receptor agonists. At 10-month follow-up, she was on a regular diet, and EGD demonstrated complete healing of the esophagus. Please see Table 1 for a timeline of the events. Pre-operative CT scan demonstrating esophagopleural fistula Follow-up esophagogastroduodenoscopy at 2-months demonstrating resolution of esophageal perforation Table 1Timeline of presentation, management, and recovery following esophageal perforation after semaglutide reinitiationTimelineEvent1-year priorInitiated semaglutide therapy and titrated slowly to 2.4 mg/week. Achieved ~ 30 lb weight lossSeveral Months PriorSemaglutide discontinued due to lapse in insurance coverage1-day prior to presentationSemaglutide restarted at 2.4 mg/week without dose titrationDay 0Presented to ED with nausea, vomiting, acute-onset chest pain in septic shockCT demonstrating pneumomediastinum and bilateral pleural effusionsEsophagram demonstrated distal esophageal perforationEGD with stent placement and NJ feeding tubeLeft sided chest tubeDay 4Extubated and weaned from vasopressorsDay 5Transferred from ICUDay 6–14Managed on NJ tube feedsCultures positive for Candida Albicans and Streptococcus Salivarius treated with Clindamycin and FluconazoleAdditional left side chest tube placedPatient discharged on inpatient day-14Day 34Repeat EGD demonstrating persistent perforation and fully covered esophageal stent was replacedDay 56Re-admitted with necrotizing pneumonia of the left lower lobeStent noted to have migrated and was retrieved endoscopicallyImaging demonstrating esophageopleural fistula and abscessDay 58Repeat endoscopy with stent placementOR with Thoracic Surgery for left thoracotomy, abscess drainage, decortication, repair of perforation, and PEG tube placement.Day 59/POD1Weaned from vasopressorsPEG tube feeds initiatedDay 60 to 68/POD2 to 9Maintained NPOChest tubes removed on POD2 and POD3Discharged from ICU on POD3Antibiotics continued until POD5Discharged on POD9 to inpatient rehabDay-72/POD14Esophagram without evidence of leakLiquid diet initiatedDay-96/POD38EGD with stent removedDiet advancement to solidsDay-136/POD78Tolerating caloric goals without tube feeds; PEG removed10-months post-operativelyAsymptomatic, tolerating general diet, and EGD with complete healing of prior perforationRecommended abstinence from GLP-1 receptor agonistsED: Emergency department. EGD: Esophagogastroduodenoscopy. NJ: Nasojejunal. ICU: Intensive care unit. PEG: Percutaneous endoscopic gastrostomy. POD: Postoperative day Timeline of presentation, management, and recovery following esophageal perforation after semaglutide reinitiation Presented to ED with nausea, vomiting, acute-onset chest pain in septic shock CT demonstrating pneumomediastinum and bilateral pleural effusions Esophagram demonstrated distal esophageal perforation EGD with stent placement and NJ feeding tube Left sided chest tube Managed on NJ tube feeds Cultures positive for Candida Albicans and Streptococcus Salivarius treated with Clindamycin and Fluconazole Additional left side chest tube placed Patient discharged on inpatient day-14 Re-admitted with necrotizing pneumonia of the left lower lobe Stent noted to have migrated and was retrieved endoscopically Imaging demonstrating esophageopleural fistula and abscess Repeat endoscopy with stent placement OR with Thoracic Surgery for left thoracotomy, abscess drainage, decortication, repair of perforation, and PEG tube placement. Weaned from vasopressors PEG tube feeds initiated Maintained NPO Chest tubes removed on POD2 and POD3 Discharged from ICU on POD3 Antibiotics continued until POD5 Discharged on POD9 to inpatient rehab Esophagram without evidence of leak Liquid diet initiated EGD with stent removed Diet advancement to solids Asymptomatic, tolerating general diet, and EGD with complete healing of prior perforation Recommended abstinence from GLP-1 receptor agonists ED: Emergency department. EGD: Esophagogastroduodenoscopy. NJ: Nasojejunal. ICU: Intensive care unit. PEG: Percutaneous endoscopic gastrostomy. POD: Postoperative day Discussion and conclusions Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, liraglutide, dulaglutide, and exenatide, are widely used therapies for type 2 diabetes mellitus and obesity [1]. These agents enhance glucose-dependent insulin secretion, inhibit glucagon release, delay gastric emptying, and promote satiety. Gastrointestinal adverse effects, particularly nausea, vomiting, abdominal discomfort, diarrhea, and delayed gastric emptying are frequently reported [2]. GLP-1 RAs delay gastric emptying by activating vagal afferent pathways, inhibiting antral contractions, and increasing pyloric sphincter tone, while suppressing gastric smooth muscle activity through reduced cholinergic and enhanced nitrergic signaling [1]. This neurohormonal mechanism slows gastric motility and reduces nutrient delivery to the duodenum. Delayed gastric emptying, while important to the weight loss mechanism of GLP-1 receptor agonists, has been implicated in complications including nausea, vomiting, symptomatic gastroparesis, bezoar formation, and perioperative aspiration. The rate of solid gastric residue during endoscopy was 3.5-fold higher in patients receiving GLP-1 receptor agonists compared to controls [3]. In addition, these agents exhibit a dose-dependent risk of nausea, most pronounced during and shortly after dose titration periods [4, 5]. Our patient resumed semaglutide at the maximum dosage (2.4 mg weekly) following a prolonged interruption, which may have precipitated more severe adverse effects due to insufficient physiological adaptation to the medication or the high starting dose. Case reports have described GLP-1 RA associated gastroparesis with symptom resolution following drug discontinuation, leading to current recommendations to withhold these agents for one week prior to elective surgical procedures. [6–7] The FDA has updated semaglutide labeling to include warnings for delayed gastric emptying, ileus, and peri-operative aspiration [8]. To the best of the authors’ knowledge, we present the first case of Boerhaave’s syndrome associated with GLP-1 RAs. Notably, while the FDA label cites Mallory-Weiss tears, representing a mucosal injury, as a reported adverse events with semaglutide, full thickness esophageal perforation has not been previously described [9]. The pathophysiology of Boerhaave’s syndrome in the setting of GLP-1 RAs remains unknown. The authors suspect that GLP-1 RA–induced delayed gastric emptying predisposes patients to severe nausea and vomiting, creating the barogenic forces necessary for esophageal rupture. In addition, GLP-1 RAs activate receptors within the area postrema of the medulla, a region that lacks a blood-brain barrier and serves as a chemoreceptor trigger zone for nausea and vomiting [1]. Stimulation of these central pathways may exacerbate emesis and contribute to the forceful retching implicated in esophageal rupture. Kuwano et al. have proposed that Boerhaave’s syndrome results from abnormal gastrointestinal motor contractions, leading to prolapse of the gastric fornix mucosa into the esophagus and excessive traction on the distal esophageal wall, particularly in anatomically vulnerable zones near the esophagogastric junction [10]. This process may be further amplified by GLP-1 RA–mediated suppression of anterograde antral contractions and increased pyloric tone, which delay gastric clearance and promote prolonged retching episodes [1]. Together, these central and peripheral mechanisms can produce a critical rise in intraesophageal pressure against a closed glottis, ultimately resulting in transmural perforation. Further research is necessary to better characterize the pathophysiology of esophageal rupture in the context of GLP-1 RA therapy. The mechanism underlying the development of the esophagopleural fistula in this patient is uncertain. Migration of fully covered self-expanding esophageal stents is a recognized complication and may contribute to localized mechanical irritation or pressure-related injury to the esophageal wall [11]. In the present case, persistent inflammation from the initial perforation, mediastinal contamination, and pleural infection may also have impaired tissue healing and increased susceptibility to fistula formation. These factors together may have contributed to the development of the esophagopleural fistula observed during the patient’s subsequent presentation. This case highlights a rare but potentially life-threatening complication associated with GLP-1 receptor agonist therapy and underscores the importance of heightened clinical awareness. While gastrointestinal adverse effects such as delayed gastric emptying, nausea, and vomiting are well documented with these agents, this is, to our knowledge, the first reported case of Boerhaave’s syndrome occurring in association with GLP-1 receptor agonist use. Although a definitive causal relationship cannot be established from a single case report, the temporal association between the resumption of high-dose GLP-1 receptor agonist therapy without titration the day prior and the subsequent onset of severe emesis in this patient, together with the known effects of these agents on gastric emptying and gastrointestinal motility, suggests that medication-related gastroparesis and vomiting may have contributed to the development of esophageal rupture. Given the widespread use of GLP-1 receptor agonists for weight management and diabetes, clinicians should maintain a high index of suspicion for esophageal injury in patients presenting with severe emesis and chest pain, particularly following recent dose titration or reinitiation of therapy. Early recognition and multidisciplinary management are essential to optimize outcomes in this rare but serious complication. Author contributions Conceptualization: Jason M. Aubrey, Geoffrey T. LamData curation: N/AFormal analysis N/AFunding acquisition: N/A​Investigation: Jason M. Aubrey, Geoffrey T. Lam​Methodology: Jason M. Aubrey, Geoffrey T. LamProject administration:​ Geoffrey T. Lam​Resources: Geoffrey T. Lam​Software: N/A​Supervision: Geoffrey T. Lam​Validation: N/A​Visualization: Jason M. Aubrey, Chance Benner, Geoffrey T. LamWriting – original draft: Jason M. Aubrey, Chance Benner, Geoffrey T. LamWriting – review & editing: Jason M. Aubrey, Chance Benner, Geoffrey T. LamApproval of final manuscript: all authors. Funding No funding was utilized. Data availability Information is available on request. Declarations Ethics approval The Corewell health IRB reviewed the case and waived the need for IRB approval. Consent for publication The patient gave consent for their case to be published. Competing interests The authors declare no competing interests. Informed consent Informed consent was obtained from the patient for publication of this case report. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Bibliography Associated Data Data Availability Statement Information is available on request.